Doctors at the University of Arizona Cancer Centre at St Joseph’s Hospital said that new treatment can improve the response rates i.e. increase the rate of tumour shrinkage and delay the progression of cancer. The researchers added that trebananib is a first-in-class peptide-Fc fusion protein that targets the angeiogenesis growth of new blood vessels into cancerous tumours by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor.
This is a completely different mechanism of action compared with other agents that also influence angiogenesis by inhibiting vascular endothelial growth factor such as bevacizumab. Researchers said that that Trebananib does not increase the risk of hypertension and bowel perforation like bevaciuzmab, but it still has similar impact on tumour shrinkage and delaying the progression of cancer.
A certain randomized clinical trial added trebananib or placebo to standard chemotherapy among 919 women with recurrent ovarian cancer patient from 179 sites in about 32 countries. The trial, which is dubbed TRINOVA-1, was run by Professor Bradley J Monk who directs the Division of Gynaecologic Oncology at the University of Arizona Cancer Centre at St Joseph’s in Phoenix. Monk said, “This is an exciting new targeted medication in treating recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal and new treatments are desperately needed”.
“TRINOVA-1 also showed that angiogenesis is a complex process in oncology and many new targets like angiopoietin 1/2 will allow us to more effectively inhibit the growth of new blood vessels that are necessary for cancer growth, metastases and progression. If we can stop cancers from growing by choking off their blood supply, we can help our patients feel better and live longer,” he added.
Article Source: financialexpress
Image Courtesy: gettyimages.in
Read more on Health News.